EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Xeris Biopharma Holdings, Inc. (XERS) had EBIT Margin of 9.52% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$83.13M |
|
$2.23M |
|
$10.57M |
|
$72.55M |
|
$75.21M |
|
$7.92M |
|
$-5.68M |
|
$2.23M |
|
$2.23M |
|
$2.23M |
|
$2.23M |
|
$2.23M |
|
$2.23M |
|
$7.92M |
|
$12.02M |
|
170.52M |
|
177.63M |
|
$0.01 |
|
$0.01 |
|
| Balance Sheet Financials | |
$251.68M |
|
$5.03M |
|
$140.33M |
|
$392.01M |
|
$118.59M |
|
$221.22M |
|
$260.41M |
|
$379.00M |
|
$13.01M |
|
$-95.22M |
|
$13.01M |
|
172.56M |
|
| Cash Flow Statement Financials | |
$9.87M |
|
$-0.33M |
|
$-8.84M |
|
$115.06M |
|
$115.77M |
|
$0.71M |
|
$4.14M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.12 |
|
-- |
|
-- |
|
0.94 |
|
17.00 |
|
87.28% |
|
9.52% |
|
|
EBIT Margin |
9.52% |
-- |
|
2.69% |
|
2.69% |
|
$9.54M |
|
-- |
|
-- |
|
-- |
|
0.21 |
|
0.14 |
|
1.48 |
|
60.95 |
|
17.17% |
|
-2.35% |
|
0.57% |
|
0.95% |
|
$0.08 |
|
$0.05 |
|
$0.06 |
|